Unio Capital LLC Sells 626 Shares of Eli Lilly and Company $LLY

Key Points

• Unio Capital LLC reduced its position in Eli Lilly and Company by 3.1%, owning 19,880 shares after selling 626 shares during the first quarter.
• In its latest earnings report, Eli Lilly reported $6.31 earnings per share (EPS), surpassing estimates, with revenues of $15.56 billion.
• Eli Lilly announced a quarterly dividend of $1.50 per share, set to be paid on September 10th, with a dividend yield of 0.8%.

Unio Capital LLC decreased its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 3.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 19,880 shares of the company's stock after selling 626 shares during the quarter. Eli Lilly and Company accounts for about 6.3% of Unio Capital LLC's holdings, making the stock its 4th biggest holding. Unio Capital LLC's holdings in Eli Lilly and Company were worth $16,419,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. WestEnd Advisors LLC raised its holdings in Eli Lilly and Company by 210.0% in the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock valued at $26,000 after acquiring an additional 21 shares in the last quarter. Wealth Preservation Advisors LLC acquired a new stake in Eli Lilly and Company in the first quarter valued at approximately $27,000. Citizens National Bank Trust Department raised its holdings in Eli Lilly and Company by 180.0% in the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after acquiring an additional 27 shares in the last quarter. Financial Gravity Asset Management Inc. acquired a new stake in Eli Lilly and Company in the first quarter valued at approximately $40,000. Finally, TD Capital Management LLC raised its holdings in Eli Lilly and Company by 129.2% in the first quarter. TD Capital Management LLC now owns 55 shares of the company's stock valued at $46,000 after acquiring an additional 31 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $726.35 on Friday. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The firm has a market cap of $687.46 billion, a PE ratio of 47.47, a price-to-earnings-growth ratio of 1.01 and a beta of 0.47. The company's 50 day simple moving average is $743.84 and its 200-day simple moving average is $781.22. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $942.35.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. The business had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company's revenue for the quarter was up 37.6% compared to the same quarter last year. During the same period last year, the firm posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, equities analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be given a dividend of $1.50 per share. The ex-dividend date is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.8%. Eli Lilly and Company's dividend payout ratio (DPR) is 39.22%.

Insider Buying and Selling at Eli Lilly and Company

In related news, Director J Erik Fyrwald purchased 1,565 shares of the firm's stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the acquisition, the director directly owned 74,578 shares in the company, valued at $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Jamere Jackson purchased 200 shares of the firm's stock in a transaction that occurred on Friday, August 8th. The shares were bought at an average cost of $639.56 per share, with a total value of $127,912.00. Following the completion of the acquisition, the director owned 9,402 shares of the company's stock, valued at approximately $6,013,143.12. This trade represents a 2.17% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders bought 4,514 shares of company stock valued at $2,894,841. 0.13% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several brokerages have commented on LLY. HSBC upgraded shares of Eli Lilly and Company from a "reduce" rating to a "hold" rating and increased their price target for the company from $675.00 to $700.00 in a research note on Wednesday, August 27th. Morgan Stanley reiterated an "overweight" rating and issued a $1,135.00 price target (up from $1,133.00) on shares of Eli Lilly and Company in a research note on Thursday, July 10th. Hsbc Global Res upgraded shares of Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a research note on Wednesday, August 27th. Deutsche Bank Aktiengesellschaft dropped their price target on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating on the stock in a research note on Monday, August 11th. Finally, Guggenheim dropped their price target on shares of Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating on the stock in a research note on Wednesday, August 13th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $950.17.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.